利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1960 条记录 (耗时 0.026 秒)

    VACCINE COMPOSITION COMPRISING ENCODED ADJUVANT
    3.
    发明公开
    VACCINE COMPOSITION COMPRISING ENCODED ADJUVANT 审中-公开

    公开(公告)号：US20240269272A1

    公开(公告)日：2024-08-15

    申请号：US18566077

    申请日：2022-06-20

    申请人： NOUSCOM AG

    发明人： Elisa SCARSELLI ,  Alfredo NICOSIA ,  Anna MORENA D'ALISE ,  Armin LAHM ,  Guido LEONI ,  Emanuele SASSO

    IPC分类号： A61K39/39 ,  A61K39/00 ,  A61P35/00 ,  C12N15/86

    CPC分类号： A61K39/39 ,  A61K39/0011 ,  A61P35/00 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55533 ,  A61K2039/55561 ,  C12N2710/10343

    摘要： The present invention relates to a vaccine composition comprising (1) a first set of one or more vectors comprising a nucleic acid encoding one or more adjuvants, wherein the first set of one or more vectors are adenoviral vectors, and (2) an antigen or a combination of antigens or a nucleic acid encoding said antigen or combination of antigens or a second set of one or more vectors comprising said nucleic acid. The invention further relates to said vaccine composition for use in the treatment or prophylaxis of a disease. In addition, the invention relates to a vaccine composition or vaccine kit for inducing an immune response comprising (1) a first nucleic acid encoding one or more adjuvants or a first set of one or more vectors comprising said first nucleic acid and (2) an antigen or a combination of antigens or a second nucleic acid encoding said second antigen or combination of antigens or a second set of one or more vectors comprising said second nucleic acid, wherein (1) is administered to a patient at a first location and (2) is administered to the patient at a second location, wherein the first location is the same or within 20 cm of the second location and the lymphatic system of the first and second location drains to the same lymph nodes. The invention also relates to a vaccination regimen comprising a first administration step comprising administration of an antigen and an encoded adjuvant, and a second administration step comprising administration of an antigen and/or an encoded adjuvant.

    SILICIFIED TUMOR CELL COMPOSITIONS AND METHODS
    10.
    发明公开
    SILICIFIED TUMOR CELL COMPOSITIONS AND METHODS 审中-公开

    公开(公告)号：US20240115676A1

    公开(公告)日：2024-04-11

    申请号：US18267878

    申请日：2021-12-14

    申请人： Rita E. Serda ,  Jimin Guo ,  UNM Rainforest Innovations

    发明人： JIMIN GUO ,  RITA E. SERDA

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P37/04

    CPC分类号： A61K39/0011 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/5152 ,  A61K2039/55561

    摘要： In one aspect, a method generally includes obtaining a dried silicified cell that has been stored for at least 24 hours without cryopreservation and rehydrating the dried silicified cell in a pharmaceutically acceptable carrier. The method can further include surface modifying the silicified cell with at least one immunogenic molecule. The method can further include administering the rehydrated silicified cell to a subject. In some embodiment, the dried silicified cell has been stored for at least 14 days without cryopreservation. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject a chemotherapeutic agent effective to treat the tumor and administering to the subject a silicified cell vaccine effective to treat the tumor.